
|Videos|June 29, 2017
Dr. Kumar Discusses Advances in the Field of Multiple Myeloma
Author(s)Shaji K. Kumar, MD
Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses advances in the field of multiple myeloma.
Advertisement
Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses advances in the field of multiple myeloma.
The field of multiple myeloma, especially in the newly diagnosed patients, is moving forward, says Kumar.
The first completely oral treatment for newly diagnosed patients with multiple myeloma is ixazomib (Ninlaro), lenalidomide (Revlimid) and dexamethasone, which is under investigation now.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































